Cargando…
Angiotensin Type-1 Receptor Blockade May Not Protect Kidney against Cisplatin-Induced Nephrotoxicity in Rats
Background. Cisplatin (CDDP) is an anticancer drug, which is accompanied with major side effects including nephrotoxicity. We tested two doses of losartan (10 and 20 mg/kg/day) against nephrotoxicity in a rat model treated with daily administration of CDDP (2.5 mg/kg/day). Methods. Five groups of ra...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045571/ https://www.ncbi.nlm.nih.gov/pubmed/24967243 http://dx.doi.org/10.1155/2014/479645 |
_version_ | 1782319342668480512 |
---|---|
author | Rastghalam, Roya Nematbakhsh, Mehdi Bahadorani, Mehrnoosh Eshraghi-Jazi, Fatemeh Talebi, Ardeshir Moeini, Maryam Ashrafi, Farzaneh Shirdavani, Soheila |
author_facet | Rastghalam, Roya Nematbakhsh, Mehdi Bahadorani, Mehrnoosh Eshraghi-Jazi, Fatemeh Talebi, Ardeshir Moeini, Maryam Ashrafi, Farzaneh Shirdavani, Soheila |
author_sort | Rastghalam, Roya |
collection | PubMed |
description | Background. Cisplatin (CDDP) is an anticancer drug, which is accompanied with major side effects including nephrotoxicity. We tested two doses of losartan (10 and 20 mg/kg/day) against nephrotoxicity in a rat model treated with daily administration of CDDP (2.5 mg/kg/day). Methods. Five groups of rats were examined. Groups 1 and 2 received losartan 10 and 20 mg/kg/day, i.p, for a period of 10 days. Group 3 received saline for 10 days, but from day 3 the animals received CDDP (2.5 mg/kg/day, i.p) for the next seven days. Groups 4 and 5 received treatment regimen the same as groups 1 and 2, but from day 3 they also received CDDP for the next seven days. At the end of the experiment, blood samples were obtained and the kidneys were removed to undergo pathological investigation and to obtain supernatant from homogenized tissue. Results. CDDP induced nephrotoxicity, but the serum levels of creatinine and blood urea nitrogen were not attenuated by losartan. The pathological findings confirmed that losartan did not have nephroprotective effect in this experimental model. Conclusion. According to the findings, losartan could not improve renal function impaired by toxicity induced by continuous doses of CDDP, and also it worsened the renal failure. |
format | Online Article Text |
id | pubmed-4045571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-40455712014-06-25 Angiotensin Type-1 Receptor Blockade May Not Protect Kidney against Cisplatin-Induced Nephrotoxicity in Rats Rastghalam, Roya Nematbakhsh, Mehdi Bahadorani, Mehrnoosh Eshraghi-Jazi, Fatemeh Talebi, Ardeshir Moeini, Maryam Ashrafi, Farzaneh Shirdavani, Soheila ISRN Nephrol Research Article Background. Cisplatin (CDDP) is an anticancer drug, which is accompanied with major side effects including nephrotoxicity. We tested two doses of losartan (10 and 20 mg/kg/day) against nephrotoxicity in a rat model treated with daily administration of CDDP (2.5 mg/kg/day). Methods. Five groups of rats were examined. Groups 1 and 2 received losartan 10 and 20 mg/kg/day, i.p, for a period of 10 days. Group 3 received saline for 10 days, but from day 3 the animals received CDDP (2.5 mg/kg/day, i.p) for the next seven days. Groups 4 and 5 received treatment regimen the same as groups 1 and 2, but from day 3 they also received CDDP for the next seven days. At the end of the experiment, blood samples were obtained and the kidneys were removed to undergo pathological investigation and to obtain supernatant from homogenized tissue. Results. CDDP induced nephrotoxicity, but the serum levels of creatinine and blood urea nitrogen were not attenuated by losartan. The pathological findings confirmed that losartan did not have nephroprotective effect in this experimental model. Conclusion. According to the findings, losartan could not improve renal function impaired by toxicity induced by continuous doses of CDDP, and also it worsened the renal failure. Hindawi Publishing Corporation 2014-03-16 /pmc/articles/PMC4045571/ /pubmed/24967243 http://dx.doi.org/10.1155/2014/479645 Text en Copyright © 2014 Roya Rastghalam et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Rastghalam, Roya Nematbakhsh, Mehdi Bahadorani, Mehrnoosh Eshraghi-Jazi, Fatemeh Talebi, Ardeshir Moeini, Maryam Ashrafi, Farzaneh Shirdavani, Soheila Angiotensin Type-1 Receptor Blockade May Not Protect Kidney against Cisplatin-Induced Nephrotoxicity in Rats |
title | Angiotensin Type-1 Receptor Blockade May Not Protect Kidney against Cisplatin-Induced Nephrotoxicity in Rats |
title_full | Angiotensin Type-1 Receptor Blockade May Not Protect Kidney against Cisplatin-Induced Nephrotoxicity in Rats |
title_fullStr | Angiotensin Type-1 Receptor Blockade May Not Protect Kidney against Cisplatin-Induced Nephrotoxicity in Rats |
title_full_unstemmed | Angiotensin Type-1 Receptor Blockade May Not Protect Kidney against Cisplatin-Induced Nephrotoxicity in Rats |
title_short | Angiotensin Type-1 Receptor Blockade May Not Protect Kidney against Cisplatin-Induced Nephrotoxicity in Rats |
title_sort | angiotensin type-1 receptor blockade may not protect kidney against cisplatin-induced nephrotoxicity in rats |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045571/ https://www.ncbi.nlm.nih.gov/pubmed/24967243 http://dx.doi.org/10.1155/2014/479645 |
work_keys_str_mv | AT rastghalamroya angiotensintype1receptorblockademaynotprotectkidneyagainstcisplatininducednephrotoxicityinrats AT nematbakhshmehdi angiotensintype1receptorblockademaynotprotectkidneyagainstcisplatininducednephrotoxicityinrats AT bahadoranimehrnoosh angiotensintype1receptorblockademaynotprotectkidneyagainstcisplatininducednephrotoxicityinrats AT eshraghijazifatemeh angiotensintype1receptorblockademaynotprotectkidneyagainstcisplatininducednephrotoxicityinrats AT talebiardeshir angiotensintype1receptorblockademaynotprotectkidneyagainstcisplatininducednephrotoxicityinrats AT moeinimaryam angiotensintype1receptorblockademaynotprotectkidneyagainstcisplatininducednephrotoxicityinrats AT ashrafifarzaneh angiotensintype1receptorblockademaynotprotectkidneyagainstcisplatininducednephrotoxicityinrats AT shirdavanisoheila angiotensintype1receptorblockademaynotprotectkidneyagainstcisplatininducednephrotoxicityinrats |